Public and private K-12 schools in states with applicable stock epinephrine laws may be eligible for free undesignated ...
Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements ...
One woman saved another's life when she gave her her EpiPen to use, but her request to be reimbursed showed just how ...
About 1 in every 10 children and teens in the U.S. has a food allergy, an abnormal immune response to a specific food. That's ...
In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study ...
Aspire Allergy & Sinus Dr. Haley Overstreet highlights new research on needle-free treatment for severe allergic reactions. Epinephrine saves lives—but too often, hesitation gets in the way. A ...
Alerje founder Javier Evelyn’s mobile auto-injector platform was recently acquired by SemPresto.
NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 ...
Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive top ...
One of the more frequent questions I get asked is, “Hey Doc, I’ve got this medicine that’s a few months past its expiration; ...
I first covered ARS Pharmaceuticals, Inc. (SPRY) for Seeking Alpha in September 2024, issuing stock with a Buy rating, shortly after its product candidate neffy, a nasal spray, was approved for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results